These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 18669417)
1. [Clinical investigation on target value of T>MIC in carbapenems]. Mikamo H; Yamagishi Y; Tanaka K; Watanabe K Jpn J Antibiot; 2008 Apr; 61(2):73-81. PubMed ID: 18669417 [TBL] [Abstract][Full Text] [Related]
2. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory]. Sumitani Y; Kobayashi Y Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209 [TBL] [Abstract][Full Text] [Related]
3. [Clinical efficacy, safety and PK-PD analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections]. Baba S; Yamanaka N; Suzuki K; Furukawa M; Furuya N; Ubukata K; Totsuka K Jpn J Antibiot; 2009 Apr; 62(2):155-77. PubMed ID: 19673357 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Moczygemba LR; Frei CR; Burgess DS Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692 [TBL] [Abstract][Full Text] [Related]
5. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations. Ramon-Lopez A; Allen JM; Thomson AH; Dheansa BS; James SE; Hanlon GW; Stewart B; Davies JG J Antimicrob Chemother; 2015 Mar; 70(3):882-90. PubMed ID: 25362574 [TBL] [Abstract][Full Text] [Related]
7. [Administration method of meropenem on the basis of PK/PD (pharmacokinetics/pharmacodynamics) in consideration of renal function]. Mikamo H; Tanaka K; Watanabe K Jpn J Antibiot; 2006 Dec; 59(6):459-67. PubMed ID: 17334063 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of a pharmacokineticpharmacodynamic approach using software to optimize the carbapenem antibiotic regimen. Ishihara N; Nishimura N; Tamaki H; Karino F; Miura K; Isobe T; Ikawa K; Morikawa N; Naora K Int J Clin Pharmacol Ther; 2015 Jun; 53(6):422-9. PubMed ID: 25828635 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. Katsube T; Yamano Y; Yano Y J Pharm Sci; 2008 Apr; 97(4):1606-14. PubMed ID: 17705288 [TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. Kays MB; Fleming MR; Cheatham SC; Chung EK; Juenke JM Ann Pharmacother; 2014 Feb; 48(2):178-86. PubMed ID: 24259653 [TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility of anaerobic and aerobic bacteria isolated from patients with mixed infections in Nicaragua. Cáceres M; Carrera E; Palma A; Berrios G; Weintraub A; Nord CE Rev Esp Quimioter; 1999 Dec; 12(4):332-9. PubMed ID: 10855012 [TBL] [Abstract][Full Text] [Related]
12. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Goff DA; Nicolau DP Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region. Kiratisin P; Keel RA; Nicolau DP Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria. Tanaka K; Mikamo H; Nakao K; Ichiishi T; Goto T; Yamagishi Y; Watanabe K Antimicrob Agents Chemother; 2009 Jan; 53(1):319-22. PubMed ID: 18955522 [TBL] [Abstract][Full Text] [Related]
15. [In vitro antibacterial activities of carbapenems against clinical isolates]. Murase M Jpn J Antibiot; 1999 Nov; 52(11):667-79. PubMed ID: 10659443 [TBL] [Abstract][Full Text] [Related]
16. [Investigation on administration method of carbapenems]. Mikamo H; Ninomiya M; Tamaya T Jpn J Antibiot; 2002 Dec; 55(6):875-81. PubMed ID: 12621741 [TBL] [Abstract][Full Text] [Related]
17. [Bacteria isolated from surgical infections and their susceptibilities to antimicrobial agents. Special references to bacteria isolated between April 1997 and March 1998]. Mashita K; Shinagawa N; Sato T; Hirata K; Katsuramaki T; Mukaiya M; Yura J; Ishibiki K; Ushijima Y; Manabe T; Takeyama H; Hasegawa M; Aikawa N; Yamazaki M; Ishikawa S; Iwai S; Kato K; Mizuno A; Kinoshita H; Morimoto K; Konaga E; Takeuchi H; Fujimoto M; Matsuura Y; Takesue Y; Tanimura H; Ohnishi H; Maeda T; Yokoyama T; Hiyama E; Tanaka N; Inoue F; Iwagaki H; Ikeda S; Yasunami Y; Fuchimoto S; Matsumoto Y; Suzuki Y; Tanaka S; Kimura H Jpn J Antibiot; 2000 Aug; 53(8):533-65. PubMed ID: 11070817 [TBL] [Abstract][Full Text] [Related]
18. Carbapenems in the USA: focus on doripenem. Lister PD Expert Rev Anti Infect Ther; 2007 Oct; 5(5):793-809. PubMed ID: 17914914 [TBL] [Abstract][Full Text] [Related]